🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Whirlwind day at #EHA25 presenting first on eligibility + longterm safety of CAR-T in 2L LBCL and then receiving this years EHA Publication Award for our ICAHT work in the Presidential Session 🙌 Grateful to share these moments with friends, collaborators and fantastic mentors!

Rakesh Popat flying the flag for the UK Myeloma community with a presentation of very impressive results with the use of trispecific antibody JNJ-5322 in the Plenary session at #EHA2025

How does pre-LD T cell composition and NK cells potentially impact #CART outcome #lymsm? Talk to Albert Suheil Atallah-Yunes #EHA25 PS2155 Yucai Wang, MD, PhD Mayo Clinic Comprehensive Cancer Center

"Patients with extramedullary disease are often excluded from relapsed and refractory trials which is why having a dedicated trial for this population was so critical", says Dr. Shaji Kumar at #EHA2025

Shaji Kumar presenting RedirecTT-1 (Ph2 tec + tal in RRMM with EMD) as Late-Breaking at #EHA2025 . Some real hope for these EMD patients, a true unmet need. ORR of 78.9% (≥CR of 54.4%), 12-mo PFS of 81%, 12-month PFS at 74.3%. Good safety #mmsm

Kudos to the sponsor and the investigators for this dedicated study in an unmet group!

Great job Kenneth Lim presenting Mayo Clinic Comprehensive Cancer Center risk factor of IEC-nerve palsy & Parkinsonism #EHA25 #mmsm Hopefully we will learn soon from CARTITUDE trials & RWE across centers whether additional early mitigating strategies could reduce the risk further International Myeloma Foundation

📢𝗝𝗼𝗶𝗻 𝘂𝘀 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 𝗳𝗼𝗿 IACH 𝗥𝗼𝘂𝗻𝗱 𝗧𝗮𝗯𝗹𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝗼𝗻: 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀 𝗼𝗻 𝗢𝘂𝘁𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗼𝗳 𝗕𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗧-𝗖𝗲𝗹𝗹 𝗘𝗻𝗴𝗮𝗴𝗲𝗿 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗳𝗼𝗿 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗠𝘆𝗲𝗹𝗼𝗺𝗮

Grazie mille, Milano! We had a great time at #EHA2025 and are sad to say arrivederci. Let’s meet again at #IMS25 in Toronto from September 17-20. Buon viaggio!

We are happy to share our recently published clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and CAR T-cell therapy in chronic lymphocytic leukemia on behalf of #ASTCT Mehdi Hamadani, MD Mazyar Shadman, MD MPH Ambuj Kumar … pubmed.ncbi.nlm.nih.gov/40514010/

Fascinating talk by DeSelm - CAR-T worked less well on tumours not irradiated. Irradiation reduces phosphethalamine which increases DAG in CAR-T, promoting cell function. #ICML2025

Dr Ansell discussing plenary abstract ICML Lugano on predicting response to CART by microenvironment signature Mayo Clinic Comprehensive Cancer Center

CONGRESS | #18ICML | PRESENTATION Patrick B Johnston, Mayo Clinic highlights results from the phase II DAILY II US trial of zamtocabtagene autoleucel in patients with R/R CNSL (N = 16). Zamto-cel was well tolerated in patients with R/R CNSL, with encouraging efficacy (ORR,

Lymphoma Hub Mayo Clinic Continue the #18ICML lakeside conversation at “Best of Lugano 2025”, an international collaboration between Mayo Clinic and ICML in Lake Tahoe, CA Oct 9-11! Dr. Patrick Johnston will be chairing our CNS lymphoma discussion. ce.mayo.edu/hematology-and…

Dr Abdullah Jalal ‘s last day in our #onconephrology Mayo Clinic Nephrology as he prepares to embark on his new journey as a consultant Mass General Brigham Nephrology. We wish you all the best working with excellent colleagues Drs Shruti Gupta, Raad Chowdhury, MD, FASN and many others !

Now in Blood Cancer Discovery: Largest RW experience with teclistamab ever! Of 509 🇺🇸 pts (88% TEC-1 🙅🏽), ORR 53% and ≥VGPR 45%. mDOR 16 mo if ≥VGPR. I like ≥VGPR focus, i.e. #MMsm M-spike not 0 yet. When occurs, DOR similar for BCMA-naive vs exposed >9 mo ago! aacrjournals.org/bloodcancerdis…

Dr. Roxana Dronca, a medical oncologist, colleague, and longtime friend, has created a lasting legacy for her daughter Maya through her visionary cancer care work at Mayo and through the Maya Dronca Foundation. Read more: mayocl.in/3IebhM6

🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH

Our latest Review summarizes the current knowledge on mortality-defining toxicities of #CARTcell therapies, beyond CRS and ICANS. Kai Rejeski & colleagues discuss underlying mechanisms of rare and long-term toxicities and how these affect timing and management, and outline key

Stay cool from the summer heat!